Ariane Trurter, aged 8, has a rare, non-functioning brain tumor. Her parents are convinced that a lot of time will be spent in the United States.
A colleague with a rare, non-functional brain tumor from Oakland hopes to give her a lot of time to the drug tested abroad.
An 8-year-old Arian Troll is fighting against aggressive malignancy in a brain structure called "Differential Inner Pontic Glioma" (DIPG) since November 2015.
This is one of the most deadly childhood complaints. On average, children with DIPG live almost a year.
Share your cancer story
Share your timetables, photos, and videos.
When diagnosing Arian, doctors told him that his parents, Sanaz and Nadim Tverter, had lived for 9 months.
* Parents can endanger the child's life
* The Taranaki couple are fighting for their two-year-old son in New York
* My mother talked about insurance six days before surgery
* A billion dollar drug company wants to be "redeemed" from the taxpayer's money
مورمورIt was difficult to cure the disease. New Zealand radiotherapy is usually recommended.
DIPG is not responsible for standard chemotherapy, and surgery is not an option because a part of the brain touches the controlled critical function, including breathing, swallowing and sleeping.
Aria has undergone many irradiation and in July 2016, scanning showed a growing tumor.
However, in the scanning of MRI in June, cancer revealed the other side of the Arian brain – the spread of the forearm, which is responsible for motorcycle, language, memory and problem solving.
"We had a great deal of fear because we thought maybe it was awesome," said Sanas Tverter.
"He spent the day we were living and the day they gave us [we thought] & # 39; maybe he's been living longer & # 39 ;.
"Then we metastasized the tumor and it really conveyed the truth that we can go anywhere."
A new neurologist, Arian, accepted biopsy.
Her parents sent the tumor to the United States for DNA sequence. It is possible that new cells can be used to treat certain genetic mutations in cancer cells.
A recent study at the University of Glasgow has revealed that Ophthalmia has been used abroad for the treatment of malignant neoplasms, possibly with anti-aging medicines.
In the United States, a trial is under way to determine whether Oaparib is effective in treating DIPG.
As tests have shown, Arian's tumors have inherited a genetic mutation that can answer the oaphthibal, and his parents have decided to try it, hoping to extend it.
Oaparib is not funded in New Zealand, so a resident of the North Coast of Auckland paid a weekly $ 7,500 a week, which is accepted every day for the past two weeks.
There was no adverse side effect on 8-year-old old man who likes computer games and plays games.
Next month, Arian has another MRI scans to see how effective it is.
According to Farmach director Lisa Williams, Oaparib has not received an application for funding for brain tumors and has not evaluated evidence of its effectiveness in the treatment of DIPG.
Children's Cancer Specialist at the Royal Children's Hospital in Melbourne Michael Sullivan has been tested in dozens of international clinical trials for DIPG, including a variety of targeted therapy for Olaparib.
"The results of these trials are still unclear, for a particular drug [Olaparib] There is no evidence to show that any particular child can heal.
"Families usually know the truth and know that they can give extra time or simplify symptoms."
According to Sullivan, the oncologists hope even though medicines can not be found yet.
"This is a cancer that we can treat in the future only by inviting families to participate in clinical trials."
He estimated approximately 10 children in Australia and New Zealand annually with DIPG diagnosis.